Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/2154
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHosaka, E.m.
dc.contributor.authorSantos, Oscar Fernando Pavão dos [UNIFESP]
dc.contributor.authorSeguro, A.c.
dc.contributor.authorVattimo, M.f.f.
dc.date.accessioned2015-06-14T13:31:11Z
dc.date.available2015-06-14T13:31:11Z
dc.date.issued2004-07-01
dc.identifierhttp://dx.doi.org/10.1590/S0100-879X2004000700006
dc.identifier.citationBrazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 37, n. 7, p. 979-985, 2004.
dc.identifier.issn0100-879X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/2154
dc.description.abstractThe frequent use of nonsteroidal anti-inflammatory drugs (NSAID) in combination with gentamicin poses the additional risk of nephrotoxic renal failure. Cyclooxygenase-1 (COX-1) is the main enzyme responsible for the synthesis of renal vasodilator prostaglandins, while COX-2 participates predominantly in the inflammatory process. Both are inhibited by non-selective NSAID such as indomethacin. Selective COX-2 inhibitors such as rofecoxib seem to have fewer renal side effects than non-selective inhibitors. The objective of the present study was to determine whether the combined use of rofecoxib and gentamicin can prevent the increased renal injury caused by gentamicin and indomethacin. Male Wistar rats (250-300 g) were treated with gentamicin (100 mg/kg body weight, ip, N = 7), indomethacin (5 mg/kg, orally, N = 7), rofecoxib (1.4 mg/kg, orally, N = 7), gentamicin + rofecoxib (100 and 1.4 mg/kg, respectively) or gentamicin + indomethacin (100 and 5 mg/kg, respectively, N = 8) for 5 days. Creatinine clearance and alpha-glutathione-S-transferase concentrations were used as markers of renal injury. Animals were anesthetized with ether and sacrificed for blood collection. The use of gentamicin plus indomethacin led to worsened renal function (0.199 ± 0.019 ml/min), as opposed to the absence of a nephrotoxic effect of rofecoxib when gentamicin plus rofexicob was used (0.242 ± 0.011 ml/min). These results indicate that COX-2-selective inhibitors can be used as an alternative treatment to conventional NSAID, especially in situations in which risk factors for nephrotoxicity are present.en
dc.format.extent979-985
dc.language.isoeng
dc.publisherAssociação Brasileira de Divulgação Científica
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.rightsAcesso aberto
dc.subjectIndomethacinen
dc.subjectRofecoxiben
dc.subjectNonsteroidal anti-inflammatory drugsen
dc.subjectAminoglycosideen
dc.subjectAcute renal failureen
dc.titleEffect of cyclooxygenase inhibitors on gentamicin-induced nephrotoxicity in ratsen
dc.typeArtigo
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationUniversidade de São Paulo Escola de Enfermagem Laboratório Experimental
dc.description.affiliationUniversidade de São Paulo Faculdade de Medicina Laboratório de Investigação Médica
dc.description.affiliationUniversidade Federal de São Paulo (UNIFESP) Departamento de Clínica Médica Divisão de Nefrologia
dc.description.affiliationUnifespUNIFESP, Depto. de Clínica Médica Divisão de Nefrologia
dc.identifier.fileS0100-879X2004000700006.pdf
dc.identifier.scieloS0100-879X2004000700006
dc.identifier.doi10.1590/S0100-879X2004000700006
dc.description.sourceSciELO
dc.identifier.wosWOS:000222450200006
Appears in Collections:Artigo

Files in This Item:
File Description SizeFormat 
S0100-879X2004000700006.pdf447.83 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.